US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

1.86

+0.10005.68%

Post-market: 1.860.0046+0.25%19:59 EDT

Volume:542.03K

Turnover:981.09K

Market Cap:200.88M

PE:-3.41

High:1.86

Open:1.78

Low:1.73

Close:1.76

52wk High:6.30

52wk Low:1.58

Shares:108.00M

Float Shares:94.28M

Volume Ratio:1.24

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5461

EPS(LYR):-0.4448

ROE:-757.48%

ROA:-37.70%

PB:16.02

PE(LYR):-4.18

Loading ...

Overview Company News Filings

BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise

NervGen Pharma Shares Down 22.3% at $2.86 Premarket After Public Offering

THOMSON REUTERS

BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of Securities

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

THOMSON REUTERS

NervGen Pharma Corp - Common Shares Sold at $2.50 per Share and Warrant

THOMSON REUTERS

NervGen Pharma secondary offering; price range $2.50-$3.68

NervGen Pharma Shares Slide After Disclosing Public Offering

NervGen Pharma launches underwritten public offering of shares and warrants

NervGen Pharma Corp - Net Proceeds to Advance Nvg-291 Clinical Studies and for General Corporate Purposes

THOMSON REUTERS

NervGen Announces Proposed Public Offering of Securities

THOMSON REUTERS

NervGen Pharma Corp - Commences Underwritten Public Offering of Common Shares, Warrants, and Pre-Funded Warrants

THOMSON REUTERS

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

NervGen Q1 FY26 net loss narrows to C$1.68 million

NervGen Pharma Corp expected to post a loss of 8 cents a share - Earnings Preview

NervGen Pharma (NGEN) Gets a Buy from Stifel Nicolaus

NervGen Pharma Initiated at Buy by HC Wainwright & Co.

NervGen Pharma appoints Keith Vendola as CFO

NervGen Pharma Strengthens Leadership Team With Appointment of Keith Vendola as Chief Financial Officer

THOMSON REUTERS

HC Wainwright Initiates Coverage on NervGen Pharma With Buy Rating, $18 Price Target

MT Newswires Live

NervGen Pharma to present at Bloom Burton Healthcare Investor Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NGEN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":1.86,"timestamp":1787342400000,"preClose":1.76,"halted":0,"volume":542033,"hourTrading":{"tag":"盘后","latestPrice":1.8646,"preClose":1.86,"latestTime":"19:59 EDT","volume":1071,"amount":1986.7876,"timestamp":1787356776851,"change":0.0046,"changeRate":0.002473,"amplitude":0.018602},"delay":0,"changeRate":0.05681818181818187,"floatShares":94281199,"shares":108000000,"eps":-0.546059,"marketStatus":"Market Closed","change":0.1,"latestTime":"08-21 16:00:00 EDT","open":1.78,"high":1.86,"low":1.7269,"amount":981087.5352752,"amplitude":0.075625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.546059,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.76,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.76,"latestTime":"09:00 EDT","volume":236,"amount":414.3536016,"timestamp":1787317237196,"change":-0.01,"changeRate":-0.005682,"amplitude":0.016023},"postHourTrading":{"tag":"盘后","latestPrice":1.8646,"preClose":1.86,"latestTime":"19:59 EDT","volume":1071,"amount":1986.7876,"timestamp":1787356776851,"change":0.0046,"changeRate":0.002473,"amplitude":0.018602},"volumeRatio":1.2377262482049183,"impliedVol":0.0812,"impliedVolPercentile":0.1497},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":94281199,"roa":"-37.70%","roe":"-757.48%","lyrEps":-0.444846,"volumeRatio":1.2377262482049183,"shares":108000000,"dividePrice":0,"high":1.86,"amplitude":0.075625,"preClose":1.76,"low":1.7269,"week52Low":1.58,"pbRate":"16.02","week52High":6.3,"institutionHeld":0,"latestPrice":1.86,"eps":-0.546059,"divideRate":0,"volume":542033,"delay":0,"ttmEps":-0.546059,"open":1.78,"prevYearClose":5.6,"prevWeekClose":1.735,"prevMonthClose":1.62,"prevQuarterClose":2.06,"fiveDayClose":1.735,"twentyDayClose":1.63,"sixtyDayClose":2.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NGEN","fiscalQuarterEnding":"2026/06","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2026-05-15","symbol":"NGEN","fiscalQuarterEnding":"2026/03","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.09},{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-08-21","current":-3.406225,"percent":0.973856,"low":-25.148356,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"high":-4.008234,"avg":-11.783719,"sd":5.689592,"marketCap":189239834},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-17","current":-10.464421,"twenty":-19.238183,"median":-17.254832,"eighty":-16.110604,"marketCap":336672423},{"date":"2026-04-24","current":-9.863583,"twenty":-18.837636,"median":-17.005665,"eighty":-12.953446,"marketCap":318058323},{"date":"2026-05-01","current":-9.064424,"twenty":-18.587877,"median":-16.950192,"eighty":-10.62677,"marketCap":293779061},{"date":"2026-05-08","current":-9.632569,"twenty":-18.344939,"median":-16.86331,"eighty":-10.287304,"marketCap":311583853},{"date":"2026-05-15","current":-9.34654,"twenty":-18.295105,"median":-16.834362,"eighty":-10.043494,"marketCap":300253531},{"date":"2026-05-22","current":-9.812417,"twenty":-18.145605,"median":-16.66306,"eighty":-9.800918,"marketCap":297825605},{"date":"2026-05-29","current":-7.287863,"twenty":-18.008563,"median":-16.66306,"eighty":-9.72533,"marketCap":220902522},{"date":"2026-06-05","current":-7.091826,"twenty":-17.902667,"median":-16.382746,"eighty":-9.634252,"marketCap":213468303},{"date":"2026-06-12","current":-6.717699,"twenty":-17.87775,"median":-16.216296,"eighty":-9.423447,"marketCap":200723927},{"date":"2026-06-18","current":-7.855923,"twenty":-17.87775,"median":-15.872071,"eighty":-9.364073,"marketCap":232584867},{"date":"2026-06-26","current":-6.880017,"twenty":-17.753166,"median":-13.39003,"eighty":-9.064424,"marketCap":202847989},{"date":"2026-07-02","current":-7.524736,"twenty":-17.753166,"median":-10.756935,"eighty":-7.674051,"marketCap":221964554},{"date":"2026-07-10","current":-6.687968,"twenty":-17.753166,"median":-10.600843,"eighty":-7.470839,"marketCap":197537832},{"date":"2026-07-17","current":-5.950494,"twenty":-17.703333,"median":-10.394273,"eighty":-7.2635,"marketCap":177359237},{"date":"2026-07-24","current":-5.990968,"twenty":-17.616125,"median":-10.19196,"eighty":-7.15871,"marketCap":177890252},{"date":"2026-07-31","current":-5.701372,"twenty":-17.597437,"median":-10.084942,"eighty":-7.057391,"marketCap":170260212},{"date":"2026-08-07","current":-6.137986,"twenty":-17.522687,"median":-9.917992,"eighty":-6.810664,"marketCap":183029728},{"date":"2026-08-14","current":-6.239509,"twenty":-17.454165,"median":-9.793252,"eighty":-6.730479,"marketCap":187286234},{"date":"2026-08-21","current":-4.207016,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"marketCap":189239834}],"updateTime":1787485585660},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637331869","title":"BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331869","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637331869?lang=en_us&edition=fundamental","pubTime":"2026-05-22 17:51","pubTimestamp":1779443507,"startTime":"0","endTime":"0","summary":"BUZZ-NervGen Pharma tumbles on deep-discounted $60 mln equity raise** NervGen Pharma NGEN.O shares tumble 29.3% premarket to $2.60, a six-month low, after $60 mln follow-on priced at steep discount** Canadian biotech late Thurs sold 24 mln shares with warrants to buy up to 24 mln shares at $2.50, a 32% discount to last sale** The 5-yr warrants are exercisable immediately with exercise price of $3.68** NGEN has ~82.2 mln shares outstanding, per LSEG data** Co intends to use net offering proceeds to fund advancement of its spinal cord injury drug, NVG-291, through clinical studies and for general corporate and working capital purposes** Leerink and TD Cowen joint bookrunners ** Through Thurs, NGEN shares lost 34% YTD** All 7 analysts rate the stock \"buy\"; median PT $8.20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL6N41Z0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391152","title":"NervGen Pharma Shares Down 22.3% at $2.86 Premarket After Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637391152?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:04","pubTimestamp":1779437091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nL4N41Z0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637186362","title":"BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637186362","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637186362?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:28","pubTimestamp":1779420528,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of SecuritiesMay 21 (Reuters) - NervGen Pharma Corp NGEN.O:NERVGEN ANNOUNCES PRICING OF US$60.0 MILLION PUBLIC OFFERING OF S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637629743","title":"NervGen Announces Pricing of US$60.0 Million Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637629743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637629743?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:27","pubTimestamp":1779420420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637621383","title":"NervGen Pharma Corp - Common Shares Sold at $2.50 per Share and Warrant","url":"https://stock-news.laohu8.com/highlight/detail?id=2637621383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637621383?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:27","pubTimestamp":1779420420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nTUA3TYWNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637368530","title":"NervGen Pharma secondary offering; price range $2.50-$3.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368530?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:50","pubTimestamp":1779403811,"startTime":"0","endTime":"0","summary":"18:49 EDT NervGen Pharma (NGEN) secondary offering; price range $2.50-$3.68 Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-secondary-offering-price-range-2-50-3-68-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-secondary-offering-price-range-2-50-3-68-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357687","title":"NervGen Pharma Shares Slide After Disclosing Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357687?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779397980,"startTime":"0","endTime":"0","summary":"Shares of NervGen Pharma slid after the company commenced an underwritten public offering of common shares and warrants.The stock declined 17% to $3.06 in after-hours trading Thursday. Shares, which began trading on Nasdaq in January, had lost more than 14% of their value in the past three months through the regular session's close.The company, which is developing neuroreparative therapeutics for spinal cord injuries, didn't detail the size of the offering. It said it intends to use proceeds from the sale to advance one of its in-development treatments through clinical studies, as well as for general corporate and working capital purposes.Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351926","title":"NervGen Pharma launches underwritten public offering of shares and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351926?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393684,"startTime":"0","endTime":"0","summary":"NervGen launched an underwritten public offering of common shares with accompanying warrants to buy common shares.Some investors may receive pre-funded warrants in lieu of common shares, also paired with common share warrants.Proceeds earmarked to advance NVG-291 through clinical studies, with the remainder for general corporate purposes.Leerink Partners, TD Cowen named as joint bookrunners.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL99qj13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","SG9999014021.USD","BK4207","SG9999014013.SGD","NGEN","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637511633","title":"NervGen Pharma Corp - Net Proceeds to Advance Nvg-291 Clinical Studies and for General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2637511633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637511633?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351953","title":"NervGen Announces Proposed Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351953?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637351168","title":"NervGen Pharma Corp - Commences Underwritten Public Offering of Common Shares, Warrants, and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2637351168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637351168?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8WBGNY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636020302","title":"NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2636020302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636020302?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:15","pubTimestamp":1779102900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA4CPV4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030458","title":"NervGen Q1 FY26 net loss narrows to C$1.68 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030458?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:35","pubTimestamp":1778877310,"startTime":"0","endTime":"0","summary":"NervGen Pharma posted a net loss of CAD 1.68 million for the three months ended March 31, 2026, narrowing from CAD 3.95 million a year earlier.Research and development expense rose to CAD 4.86 million, while general and administrative costs slipped to CAD 2.67 million.Unrealized gain on warrant derivative increased to CAD 5.72 million, helping cut the warrant derivative liability to CAD 9.35 million at quarter-end.Cash and cash equivalents fell to CAD 16.56 million as of March 31, 2026, from CAD 22.07 million at end-2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4XDnCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428279","title":"NervGen Pharma Corp  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428279","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428279?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:41","pubTimestamp":1778506865,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp  expected to post a loss of8cents a share - Earnings Preview NervGen Pharma Corp NGEN.OQ NGEN.O is expected to  report resultson May 13 (estimated) for the period ending March 31 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630358527","title":"NervGen Pharma (NGEN) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2630358527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630358527?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:35","pubTimestamp":1777386920,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on NervGen Pharma, with a price target of $6.00. Keywood co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4127","SF","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630064395","title":"NervGen Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630064395","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630064395?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:48","pubTimestamp":1777290480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGEN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 07:48 ET (11:48 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630953193","title":"NervGen Pharma appoints Keith Vendola as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2630953193","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630953193?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:32","pubTimestamp":1777289566,"startTime":"0","endTime":"0","summary":"NervGen Pharma appointed Keith Vendola as chief financial officer, effective immediately.Vendola will lead financial strategy, capital markets activity, financial planning, corporate development, and strategic initiatives.He joins from Wugen, where he served as CFO.Vendola previously served as CFO of IO Biotech, leading the company through its IPO.Earlier roles included CFO and chief strategy officer at Rezolute, plus chief of staff to CEO and vice president of competitive strategy and investor relations at Coherus BioSciences.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL7Tx2Kd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4007","IE00BKPKM429.USD","SG9999014039.USD","BK4535","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","NGEN","IE00B3QW5Z07.USD","BK4585","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","CHRS","BK4588","IOBT","IE00B64PRP62.GBP","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630930993","title":"NervGen Pharma Strengthens Leadership Team With Appointment of Keith Vendola as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630930993","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630930993?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2HRM33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393285","title":"HC Wainwright Initiates Coverage on NervGen Pharma With Buy Rating, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393285?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:21","pubTimestamp":1777288871,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp. (NGEN) has an average rating of Buy and mean price target of $10.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627303954","title":"NervGen Pharma to present at Bloom Burton Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627303954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627303954?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:45","pubTimestamp":1776080739,"startTime":"0","endTime":"0","summary":"NervGen executives scheduled to join H.C. Wainwright HCW@Home virtual fireside chat April 15, 2026.Bloom Burton Healthcare Investor Conference presentation set for April 22, 2026 in Toronto.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL5Qzzxk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","SG9999014039.USD","BK4112","BK4007","IE00BKPKM429.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NGEN","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}]}}